Plus   Neg

Nektar Publishes Two Manuscripts On Its Immuno-oncology Candidate, Bempeg

Nektar Therapeutics (NKTR), a biopharmaceutical company, published preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg), an investigational CD122-preferential interleukin-2 pathway agonist designed to provide activation and proliferation of cancer-killing immune cells. The company said the data showed that bempeg, in combination with immune-based therapies including checkpoint inhibition, antigen-specific vaccination and adoptive cell transfer therapy, enhanced T-cell mediated tumor control.

Bempeg in combination with checkpoint inhibitors and other immune-mediating agents is being evaluated in clinical trials, Nektar Therapeutics noted.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT